Companies in #Small Cell Lung Cancer (SCLC)
Found 2 companies operating in this sector.
Jazz Pharmaceuticals is a global biopharmaceutical company focused on neuroscience and oncology, with a commercial portfolio that includes Xywav (low-sodium oxybate), Epidiolex (cannabidiol), and Zepzelca (lurbinectedin). The company markets Zepzelca in the U.S. under license from PharmaMar and is facing renewed questions about the drug's accelerated approval in small cell lung cancer after a confirmatory Phase 3 trial failed to meet its primary endpoint.
Molecular Partners AG is a clinical-stage biotechnology company founded in 2004 as a spin-off from the University of Zurich and headquartered in Zurich-Schlieren, Switzerland, with US operations in Concord, Massachusetts. The company pioneered DARPin (Designed Ankyrin Repeat Protein) therapeutics. In October 2026, Molecular Partners announced a strategic pivot to transform into a dedicated targeted radiopharmaceuticals biotech, prioritizing its lead clinical DLL3 Radio-DARPin candidate MP0712 co-developed with Orano Med, while initiating a restructuring cutting up to 44% of headcount (no more than 55 roles).